Retention Rate and Predisposing Factors for Secukinumab in Patients with Axial Spondyloarthritis: Retrospective Data from Two Tertiary Hospitals in China
Background Data from open label follow-up were merely 5 years for secukinumab as second line treatment. Real world evidence from European and Korean cohort revealed retention rate up to 4 years. No data from China has been published. We aim to evauate the longterm retention rate of secukinumab in ax...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
World Scientific Publishing
2024-01-01
|
| Series: | Journal of Clinical Rheumatology and Immunology |
| Online Access: | https://www.worldscientific.com/doi/10.1142/S2661341724740389 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|